Summary
Interferon is commonly used for treatment of type C hepatitis, but the effects are variable and many factors may be responsible. Hepatitis C virus (HCV) can be classified into 4 types, PT, Kl, K2a and K2b. Therefore, the responses to interferon treatment in patients with the different HCV genotypes were analyzed. Twenty-four patients with type C hepatitis were treated with 3 to 10 million units of various types of interferon for more than 8 weeks. HCV-RNA encoding the NS5 region (HCV-NS5) was positive in these 24 patients, 16 of which were classified with the Kl type and 8 with the K2 type of HCV. In all patients except for 2, HCV-NS5 became negative within 3 weeks of treatment without relation to the HCV genotypes. Serum alanine aminotransferase levels were normalized in 7 out of 8 patients in the K2 group and in 4 out of 16 patients in the Kl group at the end of 8 weeks. At the 24th week, ALT levels were normalized in 5 out of 6 patients in the K2 group, and in one out of 9 patients in the K1 group. The percentage of patients exhibiting a good response was significantly higher in the K2 group than in the K1 group at both observation periods. During the post-treatment periods, relapse following complete response was found in 3 patients in the K2 group and in one patient in the K1 group. The final effects of interferon were significantly better in the K2 group than in the K1 group. These results indicate that the effects of interferon were significantly better in patients in the K2 group than in patients in the K1 group. Normalization of serum ALT levels was found in two patients with cirrhosis in the K2 group, but in none of the cirrhosis patients in the Kl group, suggesting that effects of interferon may not be related to the progression of liver disease in patients in the K2 group. These results suggest that genotypes of HCV are one of the major determinants of the effect of interferon treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986;315:1575–1578.
Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter randomized, controlled trial. N Engl J Med 1989;321:1501–1506.
DiBisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321: 1506–1510.
Davis GL. Recombinant alpha-interferon treatment of non-A, non-B (type C) hepatitis: review of studies and recommendations for treatment. J Hepatol 1990;11:S72-S77.
Saracco G, Rosina F, Torrani Cerenzia MR, et al. A randomized controlled trial of interferon alpha-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990;11:S43-S49.
Ferenci P, Vogel W, Pristautz H, et al. One-year treatment of chronic non-A, non-B hepatitis with interferon alpha-2b. J Hepatol 1990;11:S50-S53.
Weiland O, Schvarcz R, Wejstal R, et al. Therapy of chronic posttransfusion non-A, non-B hepatitis with interferon alpha-2b: Swedish experience. J Hepatol 1990;11:S57-S62.
Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497–502.
Marcellin P, Boyer N, Giostra E, et al. Recombinant human alphainterferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France. Hepatology, 1991;13:393–397.
Fujioka S, Hino K, Fukuhara A, et al. Treatment of chronic non-A, non-B hepatitis: Comparative study of dosage of human interferon-beta. Acta Hepat Jap 1989;30:516–521. (in Japanese)
Enomoto N, Takada N, Takase S, et al. Nucleotide sequences and subtypes of hepatitis C virus genomes. Gastroentrol Jpn 1990; 25:405.
Enomoto N, Takada A, Nakao T, et al. There are two major types of hepatitis C virus in Japan. Biochem Biophys Res Commun 1990;170:1021–1025.
Takada N, Takase S, Enomoto N, et al. Clinical backgrounds of the patients having different types of hepatitis C virus genomes. J Hepatol 1992;14:35–40.
Enomoto N, Takada N, Takase S, et al. Hepatitis C virus RNA genome in plasma of patients with non-A, non-B hepatitis. Gastroenterol Jpn 1991;26:42–46.
Okamoto H, Okada S, Sugiyama Y, et al. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med 1990;60:215–222.
Houghton M, Choo QL, Kuo G. NANBV diagnostics and vaccines. European Patent Application 1989;0 318 216 Al.
Nakao T, Enomoto N, Takada N, et al. Typing of hepatitis C virus genomes by restriction fragment length polymorphism. J Gen Virol 1991;72:2105–2112.
Takada N, Takase S, Takada A, et al. Genotyping of hepatitis C virus and its clinical significance. Acta Hepat Jap 1992;33:121–125. (in Japanese)
Ichida F, Suzuki H, Fijisawa A, et al. A double-blind multi-center controlled study of human lymphoblastoid interferon (HLBI) in chronic hepatitis C. Kan Tan Sui 1992;25:559–579. (in Japanese)
Iino S, Hino K, Kuroki T, et al. Interferon alpha-2b treatment for chronic hepatitis C -A multicenter study-. The Clinical Report 1992;26:1149–1177. (in Japanese)
Takase S, Takada N. Detection and clinical significance of HCV-RNA. Kan Tan Sui 1992;24:15–23. (in Japanese)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takada, N., Takase, S. & Takada, A. Effects of genotypes of hepatitis C virus on interferon treatment for chronic type C hepatitis. Gastroenterol Jpn 28, 268–275 (1993). https://doi.org/10.1007/BF02779230
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02779230